Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients

Table 3B Immunological and clinical response in patients vaccinated with mDC

Patient ID	No. of Vaccinations	Antigens (Type of Lysate)	Median No. of Administered Cells × 10⁶(range)	DTH Best Response after 4 or More Vaccinations		Vitiligo	Clinical Response	Response Duration (Months)	Overall Survival (Months)
				L/H	KLH
9 P.M.	7	L	11.4 (9 – 24.1)	-	-		PR	3	14
10 P.M.	15	L	15 (2.8 – 24)	++	++++		MR	6	22
11 R.L.	10	H	9.5 (4 – 13.4)	-	++		SD	9	14
12 G.D.	16	L/H	12.6 (2.8 – 20.8)	++	+++	+	CR	8	32+
13 R.G.	4	H	9.3 (8 – 26)	-	+++		PD	-	8
14 T.A.	13	H	9 (1.2 – 12)	-	++		MR	12	28+
15 B.A.	4	H	5.9 (3.7 – 12)	-	-		PD	-	7
16 C.P.	6	H	7.8 (1.6 – 15)	-	++		PD	-	20
17 O.M.	4	H	11.5 (10 – 21)	-	-		PD	-	5
18 L.B.	4	L	12.5 (10 – 15.5)	-	-		PD	-	3
19 M.J.L.	8	L	6 (2.2 – 10)	+	+++	+	SD	7+	7+
20 O.G.	5	L	10 (8.8 – 12.3)	-	-		PD	-	3
21 M.R.	4	L	9.2 (8 – 10)	+	++		SD (u.t.)	3+	3+
No. of Patients	Administration Route	Site	No. of Inoculations
13 mDC	13 i.d.	10 inguinal and 3 axillary	8–10

DTH, delayed-type hypersensitivity; L, autologous lysate; H, autologous homogenate; KLH, keyhole limpet hemocyanin.
PD, progressive disease; MR, mixed response; SD, stabilization; PR, partial response; CR, complete response; u.t., undergoing treatment.
i.d., intradermal; s.c., subcutaneous

ISSN: 1479-5876